Skip to main content
SpringerLink
Log in

Allergen-spezifische Immuntherapie bei Kindern und Jugendlichen

Fakten und häufig gestellte Fragen (FAQs)

  • Allergologie
  • Published:
Pädiatrie & Pädologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Referenzen

  1. Regulation of (EC) No 1901/2006 the Euopean Parliament and of the Council of December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://eceuropaeu/enterprise/pharmaceuticals/eudralex/vol1/reg_2006_1901/reg_2006_1901_enpdf

  2. Abramson MJ, Puy RM, Weiner JM (2003) Allergen immunotherapy for asthma. Cochrane Database Syst Rev:CD001186

  3. Akdis CA, Blesken T, Akdis M, Wuthrich B and Blaser K (1998). Role of interleukin 10 in specific immunotherapy. J Clin Invest 102: 98–106

    Article  CAS  PubMed  Google Scholar 

  4. Akdis M (2009). Immune tolerance in allergy. Curr Opin Immunol 21: 700–707

    Article  CAS  PubMed  Google Scholar 

  5. Akdis M and Akdis CA (2007). Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119: 780–791

    Article  CAS  PubMed  Google Scholar 

  6. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K and Akdis CA (2004). Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199: 1567–1575

    Article  CAS  PubMed  Google Scholar 

  7. Ariano R, Kroon AM, Augeri G, Canonica GW and Passalacqua G (1999). Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 54: 313–319

    Article  CAS  PubMed  Google Scholar 

  8. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H (2006) Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368:733-743

    Google Scholar 

  9. Bahceciler NN, Isik U, Barlan IB and Basaran MM (2001). Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 32: 49–55

    Article  CAS  PubMed  Google Scholar 

  10. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J and Saloga J (1997). Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 27: 1131–1139

    Article  CAS  PubMed  Google Scholar 

  11. Bernardini R, Campodonico P, Burastero S, Azzari C, Novembre E, Pucci N, Massai C, De Martino M and Vierucci A (2006). Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebocontrolled study. Curr Med Res Opin 22: 1515–1522

    Article  CAS  PubMed  Google Scholar 

  12. Bernardini R, Pecora S, Milani M and Burastero SE (2008). Natural rubber latex allergy in children: clinical and immunological effects of 3-years sublingual immunotherapy. Eur Ann Allergy Clin Immunol 40: 142–147

    CAS  PubMed  Google Scholar 

  13. Beyer K and Wahn U (2008). Oral immunotherapy for food allergy in children. Curr Opin Allergy Clin Immunol 8: 553–556

    Article  PubMed  Google Scholar 

  14. Bohle B (2007). The impact of pollen-related food allergens on pollen allergy. Allergy 62: 3–10

    Article  CAS  PubMed  Google Scholar 

  15. Bordignon V and Parmiani S (2003). Variation of the skin end-point in patients treated with sublingual specific immunotherapy. J Investig Allergol Clin Immunol 13: 170–176

    CAS  PubMed  Google Scholar 

  16. Bousquet J, Lockey R and Malling HJ (1998). Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102: 558–562

    Article  CAS  PubMed  Google Scholar 

  17. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, Creticos PJ, Dayer JM, Durham SR, Demoly P, Goldstein RJ, Ishikawa T, Ito K, Kraft D, Lambert PH, Lowenstein H, Muller U, Norman PS, Reisman RE, Valenta R, Valovirta E, Yssel H (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81:401-405.

    Google Scholar 

  18. Bousquet J, Van Cauwenberge P and Khaltaev N (2001). Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108: S147–334

    Article  CAS  PubMed  Google Scholar 

  19. Brewczynski PZ and Kroon AM (1999). Wirksamkeit und Verträglichkeit einer Immuntherapie mit modifizierten Gräserpollenallergenen. Allergologie 22: 411–420

    Google Scholar 

  20. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F (2009) Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123:167-173 e167

    Google Scholar 

  21. Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T and Braun W (2004). Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 59: 498–504

    Article  CAS  PubMed  Google Scholar 

  22. Businco L, Zannino L, Cantani A, Corrias A, Fiocchi A and La Rosa M (1995). Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study. Pediatr Allergy Immunol 6: 44–47

    Article  CAS  PubMed  Google Scholar 

  23. Cadario G, Galluccio AG, Pezza M, Appino A, Milani M, Pecora S and Mastrandrea F (2007). Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin 23: 2503–2506

    Article  CAS  PubMed  Google Scholar 

  24. Cady CT, Powell MS, Harbeck RJ, Giclas PC, Murphy JR, Katial RK, Weber RW, Hogarth PM, Johnson S, Bonvini E, Koenig S, Cambier JC IgGantibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett 130:57-65

  25. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S (2007) Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev:CD001936

  26. Caminiti L, Passalacqua G, Barberi S, Vita D, Barberio G, De Luca R and Pajno GB (2009). A new protocol for specific oral tolerance induction in children with IgE-mediated cow’s milk allergy. Allergy Asthma Proc 30: 443–448

    Article  CAS  PubMed  Google Scholar 

  27. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E (2007) Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62:317-324

    Google Scholar 

  28. Clark AT, Islam S, King Y, Deighton J, Anagnostou K and Ewan PW (2009). Successful oral tolerance induction in severe peanut allergy. Allergy 64: 1218–1220

    Article  CAS  PubMed  Google Scholar 

  29. Clavel R, Bousquet J, Andre C (1998) Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53:493-498.

    Google Scholar 

  30. Coifman RE, Cox LS (2007) 2006 American Academy of Allergy, Asthma & Immunology member immunotherapy practice patterns and concerns. J Allergy Clin Immunol 119:1012-1013

    Google Scholar 

  31. Compalati E, Penagos M, Tarantini F, Passalacqua G and Canonica GW (2009). Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 102: 22–28

    Article  PubMed  Google Scholar 

  32. de Blay F, Barnig C, Kanny G, Purohit A, Leynadier F, Tunonde de Lara JM, Chabane H, Guerin L (2007). Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 99: 453–461

    Article  PubMed  Google Scholar 

  33. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP and Bousquet J (1997). Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 99: 450–453

    Article  CAS  PubMed  Google Scholar 

  34. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, Canonica GW and Passalacqua G (2003). Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33: 206–210

    Article  CAS  PubMed  Google Scholar 

  35. Dolz I, Martinez-Cocera C, Bartolome JM and Cimarra M (1996). A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 51: 489–500

    CAS  PubMed  Google Scholar 

  36. Drachenberg KJ, Heinzkill M, Urban E and Woroniecki SR (2003). Efficacy and tolerability of shortterm specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MLP) for children and adolecents. Allergol et Immunopathol 31: 270–277

    Article  CAS  Google Scholar 

  37. Drachenberg KJ, Pfeiffer P, Urban E (2001) Sublinguale Immuntherapie. Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Multicenterstudie mit einem standardisierten Birken- und Gräser-/ Roggenpollenextrakt. Allergologie 24:525-534

    Google Scholar 

  38. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S (1986) A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 41:131-140

    Google Scholar 

  39. Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C,Bahceciler NN, Barlan IB Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 40:922-932

  40. Eng PA, Borer-Reinhold M, Heijnen IA and Gnehm HP (2006). Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 61: 198–201

    Article  CAS  PubMed  Google Scholar 

  41. Eng PA, Reinhold M and Gnehm HP (2002). Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 57: 306–312

    Article  CAS  PubMed  Google Scholar 

  42. Evans R, Pence H, Kaplan H and Rocklin RE (1976). The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest 57: 1378–1385

    Article  CAS  PubMed  Google Scholar 

  43. Faith A, Richards DF, Verhoef A, Lamb JR, Lee TH and Hawrylowicz CM (2003). Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin Exp Allergy 33: 1209–1215

    Article  CAS  PubMed  Google Scholar 

  44. Feliziani V, Lattuada G, Parmiani S, Dall‘Aglio PP (1995) Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 23:224-230.

    Google Scholar 

  45. Fontana V, Holt LJ and Mainland D (1966). Effectiveness of hyposensitization therapy in ragweed hay-fever in children. JAMA 195: 985–992

    Article  CAS  PubMed  Google Scholar 

  46. Francis JN, Till SJ and Durham SR (2003). Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111: 1255–1261

    Article  CAS  PubMed  Google Scholar 

  47. Gafvelin G, Thunberg S, Kronqvist M, Gronlund H, Gronneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J, Niederberger V, Akdis CA, Cromwell O, Pauli G, Valenta R, van Hage M (2005) Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138:59-66

    Google Scholar 

  48. Gillissen A, Bergmann KC, Kleine-Tebbe J, Schultze-Werninghaus G, Virchow JC, Jr., Wahn U, Graf von der Schulenburg JM (2003) [Specific immunotherapy in allergic asthma]. Dtsch Med Wochenschr 128:204–209

  49. Gleich GJ, Zimmermann EM, Henderson LL and Yunginger JW (1982). Effect of im-munotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 70: 261–271

    Article  CAS  PubMed  Google Scholar 

  50. Glover MT and Atherton DJ (1992). A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 22: 440–446

    Article  CAS  PubMed  Google Scholar 

  51. Golden DB (2006). Insect allergy in children. Curr Opin Allergy Clin Immunol 6: 289–293

    Article  PubMed  Google Scholar 

  52. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG and Lichtenstein LM (2004). Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 351: 668–674

    Article  CAS  PubMed  Google Scholar 

  53. Gotzsche PC and Johansen HK (2008). House dust mite control measures for asthma: systematic review. Allergy 63: 646–659

    Article  CAS  PubMed  Google Scholar 

  54. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Rufin P, Basset D, Fadel R and Andre C (2002). Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 129: 248–253

    Article  CAS  PubMed  Google Scholar 

  55. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C and Lowenstein H (1995). Longterm follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 96: 879–885

    Article  CAS  PubMed  Google Scholar 

  56. Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW (2009) Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 124:286-291, 291 e281-286

    Google Scholar 

  57. Horst M, Hejjaoui A, Horst V, Michel FB and Bousquet J (1990). Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 85: 460–472

    Article  CAS  PubMed  Google Scholar 

  58. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG and Sertdemir Y (2007). Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 17: 85–91

    CAS  PubMed  Google Scholar 

  59. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S and Frediani T (2003). Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 14: 216–221

    Article  PubMed  Google Scholar 

  60. Itoh N, Itagaki Y, Kurihara K Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up. Allergol Int 59:43–51

  61. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Norberg LA, Valovirta E, Wahn U and Moller C (2007). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62: 943–948

    Article  CAS  PubMed  Google Scholar 

  62. Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K, Simard JJ, Storni T, Senti G, Bot A, Wuthrich B and Kundig TM (2005). Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 35: 568–574

    Article  CAS  PubMed  Google Scholar 

  63. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124:292-300, 300 e291-297

    Google Scholar 

  64. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K and Akdis CA (2003). IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33: 1205–1214

    Article  CAS  PubMed  Google Scholar 

  65. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C and Muller UR (1995). Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154: 4187–4194

    CAS  PubMed  Google Scholar 

  66. Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C and Kalayci O (2006). The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 17: 396–407

    Article  PubMed  Google Scholar 

  67. Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C, Francis JN, Ebner C, Bohle B (2007) Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 119:937–943

    Google Scholar 

  68. Kleine-Tebbe J, Bergmann KC, Friedrichs F, Fuchs T, Jung K, Klimek L, Kühr J, Lässig W, Lepp U, Niggemann B, Rakoski J, Rebien W, Renz H, Saloga J, Simon J, Sitter H, Virchow C, Worm M (2006) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 15:56-74

    Google Scholar 

  69. Kleine-Tebbe J, Bufe A, Ebner C, Eigenmann P, Friedrichs F, Fuchs T, Huttegger I, Jung K, Klimek L, Kopp M, Lässig W, Merk HF, Niggemann B, Rabe U, Saloga J, Schmid-Grendelmeier P, Sitter H, Virchow C, Wagenmann M, Wedi B, Worm M (2009) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 18:508-537

    Google Scholar 

  70. Kopp MV, Niggemann B, Forster J (2009) House dust mite allergy: complete removal of the provoking allergen is a primary therapeutic approach. Allergy 64:1402-1403; author reply 1405

    Google Scholar 

  71. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA and Canonica GW (1999). Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 104: 425–432

    Article  CAS  PubMed  Google Scholar 

  72. Larche M, Akdis CA and Valenta R (2006). Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6: 761–771

    Article  CAS  PubMed  Google Scholar 

  73. Leroy B, Lachapelle JM, Jacquemin MG and Saint-Remy JM (1993). Immunotherapy of atopic dermatitis by injections of antigen-antibody complexes. Dermatology 186: 276–277

    Article  CAS  PubMed  Google Scholar 

  74. Leynadier F, Herman D, Vervloet D and Andre C (2000). Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 106: 585–590

    Article  CAS  PubMed  Google Scholar 

  75. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, Carr VA and Robinson DS (2004). Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363: 608–615

    Article  CAS  PubMed  Google Scholar 

  76. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L and Ventura A (2008). Specific oral tolerance induction in children with very severe cow‘s milk-induced reactions. J Allergy Clin Immunol 121: 343–347

    Article  CAS  PubMed  Google Scholar 

  77. Löwer J, Becker W-M, Vieths S (2003) Regulatory control and standardization of allergenic extracts. Frankfurt/Main: Druck- und Verlagshaus Sperlich Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe:65–115

  78. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D (2001) Neubewertung des Risikos von Testund Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44:709–718

  79. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, Stefani E and Tierno E (2003). Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 16: 73–79

    CAS  PubMed  Google Scholar 

  80. Madsen F (2007) EAACI , Standards for practical allergen-specific immunotherapy‘. Allergy 62:332

    Google Scholar 

  81. Malling HJ (1999) [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases]. Wien Med Wochenschr 149:410-414

    Google Scholar 

  82. Malling HJ (2000). Minimising the risks of allergenspecific injection immunotherapy. Drug Saf 23: 323–332

    Article  CAS  PubMed  Google Scholar 

  83. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM and Essayan DM (1998). Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 101: 506–513

    Article  CAS  PubMed  Google Scholar 

  84. Marcucci F, Sensi L, Di Cara G, Incorvaia C and Frati F (2005). Dose dependence of immunological response to sublingual immunotherapy. Allergy 60: 952–956

    Article  CAS  PubMed  Google Scholar 

  85. Marcucci F, Sensi L, Frati F, Bernardini R, Novembre E, Barbato A and Pecora S (2003). Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 58: 657–662

    Article  CAS  PubMed  Google Scholar 

  86. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G and Parmiani S (2000). Specific sublingual immunotherapy in atopic dermatitis. Results of a 6- year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr) 28: 54–62

    CAS  Google Scholar 

  87. Menardo JL, Bousquet J, Ville G, Michel FB (1983) [Desensitisation with hymenoptera venom in children]. Arch Fr Pediatr 40:543-547

  88. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E and Wahn U (2002). Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109: 251–256

    Article  PubMed  Google Scholar 

  89. Mortemousque B, Bertel F, De Casamayor J, Verin P and Colin J (2003). House-dust mite sublingualswallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 33: 464–469

    Article  CAS  PubMed  Google Scholar 

  90. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F and Blaser K (1998). Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 101: 747–754

    Article  CAS  PubMed  Google Scholar 

  91. Niggemann B and Beyer K (2007). Pitfalls in doubleblind, placebo-controlled oral food challenges. Allergy 62: 729–732

    Article  CAS  PubMed  Google Scholar 

  92. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR (2004) Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172:3252–3259

    Google Scholar 

  93. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R and Vierucci A (2004). Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114: 851–857

    Article  CAS  PubMed  Google Scholar 

  94. Pajno GB, Barberio G, De Luca F, Morabito L and Parmiani S (2001). Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31: 1392–1397

    Article  CAS  PubMed  Google Scholar 

  95. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, Canonica GW and Passalacqua G (2007). Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 120: 164–170

    Article  CAS  PubMed  Google Scholar 

  96. Pajno GB, Peroni DG, Barberio G and Boner AL (2003). Efficacy of sublingual immunotherapy in asthma and eczema. Chem Immunol Allergy 82: 77–88

    Article  CAS  PubMed  Google Scholar 

  97. Passalacqua G and Durham SR (2007). Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 119: 881–891

    Article  PubMed  Google Scholar 

  98. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, Mothes N, Spitzauer S, Montagut A, Galvain S, Melac M, Andre C, Poulsen LK and Malling HJ (2008). Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 122: 951–960

    Article  CAS  PubMed  Google Scholar 

  99. Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V, Kraft D, Valenta R (2000) Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 30:1076-1084

    Google Scholar 

  100. Piconi S, Trabattoni D, Saresella M, Iemoli E, Schenal M, Fusi A, Borelli M, Chen L, Mascheri A and Clerici M (2007). Effects of specific immunotherapy on the B7 family of costimulatory molecules in allergic inflammation. J Immunol 178: 1931–1937

    CAS  PubMed  Google Scholar 

  101. Plewako H, Wosinska K, Arvidsson M, Bjorkander J, Hakansson L and Rak S (2006). Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy. Ann Allergy Asthma Immunol 97: 464–468

    Article  CAS  PubMed  Google Scholar 

  102. Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S and Andre C (1999). Sublingualswallow immunotherapy (SLIT) with a standardized five-grass- pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 54: 819–828

    Article  CAS  PubMed  Google Scholar 

  103. Przybilla B, Rueff F (1999) [Desensitization of allergy to hymenoptera venoms]. Wien Med Wochenschr 149:421-428

    Google Scholar 

  104. Purello-D‘Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S and Ricciardi L (2001). Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 31: 1295–1302

    Article  PubMed  Google Scholar 

  105. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R, Weber B, Fiebig H, 5van Hage M, Pauli G, Valenta R and Cromwell O (2008). Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38: 1514–1525

    Article  CAS  PubMed  Google Scholar 

  106. Reha CM and Ebru A (2007). Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 35: 44–51

    Article  CAS  Google Scholar 

  107. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG and Passalacqua G (2005). Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 35: 560–564

    Article  PubMed  Google Scholar 

  108. Ring J (1982). Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 107: 597–602

    Article  CAS  PubMed  Google Scholar 

  109. Roder E, Berger MY, de Groot H, Gerth van Wijk R (2008). Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 38: 1659–1667

    Article  CAS  PubMed  Google Scholar 

  110. Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F and Tabar AI (2006). Once daily sublingual immunotherapy without updosing--A new treatment schedule. Int Arch Allergy Immunol 140: 321–326

    Article  CAS  PubMed  Google Scholar 

  111. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, Kuehr J, Zielen S, Schauer U, Kamin W, Von Berg A, Hammermann J, Weinkauf B, Weidinger G, Stenglein S and Wahn U (2004). The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59: 973–979

    Article  CAS  PubMed  Google Scholar 

  112. Rolinck-Werninghaus C, Staden U, Mehl A, Hamelmann E, Beyer K and Niggemann B (2005). Specific oral tolerance induction with food in children: transient or persistent effect on food allergy?. Allergy 60: 1320–1322

    Article  CAS  PubMed  Google Scholar 

  113. Rueff F and Przybilla B (2004). Venom immunotherapy: adverse reactions and treatment failure. Curr Opin Allergy Clin Immunol 4: 307–311

    Article  PubMed  Google Scholar 

  114. Rueff F, Wenderoth A and Przybilla B (2001). Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108: 1027–1032

    Article  CAS  PubMed  Google Scholar 

  115. Sabbah A, Hassoun S, Le Sellin J, Andre C and Sicard H (1994). A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 49: 309–313

    Article  CAS  PubMed  Google Scholar 

  116. Sampson HA, Munoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA and Decker WW et al. (2005). Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 115: 584–591

    Article  PubMed  Google Scholar 

  117. Savolainen J, Jacobsen L and Valovirta E (2006). Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 61: 1184–1190

    Article  CAS  PubMed  Google Scholar 

  118. Schafer T, Ring J (1997) Epidemiology of allergic diseases. Allergy 52:14-22; discussion 35-16.

  119. Schuetze GE, Forster J, Hauk PJ, Friedl K and Kuehr J (2002). Bee-venom allergy in children: long-term predictive value of standardized challenge tests. Pediatr Allergy Immunol 13: 18–23

    Article  PubMed  Google Scholar 

  120. Secrist H, Chelen CJ, Wen Y, Marshall JD and Umetsu DT (1993). Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178: 2123–2130

    Article  CAS  PubMed  Google Scholar 

  121. Sheikh A, Shehata YA, Brown SG and Simons FE (2009). Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy 64: 204–212

    Article  CAS  PubMed  Google Scholar 

  122. Sicherer SH, Sampson HA (2007) Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol 120:491-503; quiz 504-495

    Google Scholar 

  123. Simons FE (2003). H1-Antihistamines: more relevant than ever in the treatment of allergic disorders. J Allergy Clin Immunol 112: S42–52

    Article  CAS  PubMed  Google Scholar 

  124. Simons FE (2004). First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 113: 837–844

    CAS  PubMed  Google Scholar 

  125. Simons FE, Gu X, Johnston LM and Simons KJ (2000). Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis?. Pediatrics 106: 1040–1044

    Article  CAS  PubMed  Google Scholar 

  126. Sopo SM, Onesimo R, Giorgio V, Fundaro C Specific oral tolerance induction (SOTI) in pediatric age: clinical research or just routine practice? Pediatr Allergy Immunol 21:e446–449.

  127. Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B and Beyer K (2007). Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 62: 1261–1269

    Article  CAS  PubMed  Google Scholar 

  128. Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M and Jerzynska J (2009). Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 39: 401–408

    Article  CAS  PubMed  Google Scholar 

  129. Stewart GE, 2nd, Lockey RF (1992) Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 90:567–578

    Google Scholar 

  130. Szepfalusi Z, Emminger W, Eitelberger F, Gotz M, Grillenberger A, Horak E, Huttegger I, Koller D, Litscher H, Schmitzberger R, Varga EM, Riedler J (2009) [Allergen-specific Immunotherapy for children and adolescents - a review on available products in Austria]. Wien Klin Wochenschr 121:648-660

    Google Scholar 

  131. Szepfalusi Z, Gruber S, Eiwegger T, Dehlink E (2010) Allergen-specific immunotherapy in children: facts and FAQs. Eur J Pediatr 169

  132. Tabar AI, Anda M, Bonifazi F, Bilo MB, Leynadier F, Fuchs T, Ring J, Galvain S and Andre C (2006). Specific immunotherapy with standardized latex extract versus placebo in latex-allergic patients. Int Arch Allergy Immunol 141: 369–376

    Article  PubMed  Google Scholar 

  133. Tabar AI, Lizaso MT, Garcia BE, Gomez B, Echechipia S, Aldunate MT, Madariaga B and Martinez A (2008). Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr Allergy Immunol 19: 67–75

    PubMed  Google Scholar 

  134. Tari MG, Mancino M and Monti G (1990). Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study Allergol Immunopathol (Madr) 18: 277–284

    CAS  Google Scholar 

  135. Thalhamer T, Dobias H, Stepanoska T, Proll M, Stutz H, Dissertori O, Lackner P, Ferreira F, Wallner M, Thalhamer J, Hartl A Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. J Allergy Clin Immunol 125:926–934 e910

  136. Till S, Walker S, Dickason R, Huston D, O‘Brien F, Lamb J, Kay AB, Corrigan C and Durham S (1997). IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 110: 114–121

    Article  CAS  PubMed  Google Scholar 

  137. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, Delecluse P and Andre C (2004). Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 59: 491–497

    Article  CAS  PubMed  Google Scholar 

  138. Ullrich D, Thum-Oltimer S, Mussler S, Jaeschke B (2007) Successful specific subcutaneous immunotherapy (SCIT) with non-modified semi-depot pollen and mite preparations. Allergo J:193-198

  139. Urbanek R, Forster J, Kuhn W and Ziupa J (1985). Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 107: 367–371

    Article  CAS  PubMed  Google Scholar 

  140. Valenta R, Vrtala S, Focke-Tejkl M, Twardosz A, Swoboda I, Bugajska-Schretter A, Spitzauer S and Kraft D (2002). Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy. Clin Allergy Immunol 16: 495–517

    CAS  PubMed  Google Scholar 

  141. Valentine MD, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M and Lichtenstein LM (1990). The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 323: 1601–1603

    Article  CAS  PubMed  Google Scholar 

  142. Valovirta E, Jacobsen L, Ljorring C, Koivikko A and Savolainen J (2006). Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 61: 1177–1183

    Article  CAS  PubMed  Google Scholar 

  143. van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S and Wurtzen PA (2004). A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 34: 420–428

    Article  PubMed  Google Scholar 

  144. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C and Papageorgiou PS (1998). Doubleblind, placebo controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 53: 662–672

    Article  CAS  PubMed  Google Scholar 

  145. Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ and Durham SR (2002). Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 105: 56–62

    Article  CAS  PubMed  Google Scholar 

  146. Wachholz PA, Soni NK, Till SJ and Durham SR (2003). Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 112: 915–922

    Article  CAS  PubMed  Google Scholar 

  147. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, Le Gall M (2009) Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 123:160-166 e163

    Google Scholar 

  148. Warner JO, Price JF, Soothill JF and Hey EN (1978). Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2: 912–915

    Article  CAS  PubMed  Google Scholar 

  149. Weisnagel J (1979) Nouvel agent hyposensibilisant dans le traitement de la rhinite allergique saisonniere (fievre des foins) a l´herbe a poux chez lnfant: le MRTA (modified ragweed tyrosine adsorbate). Union Med Can 108:685-690

    Google Scholar 

  150. Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T and Gerdsen R (2003). Safety of rush insect venom immunotherapy. The results of a retrospective study in 178(patients. Allergy 58): 1176–1179

    Google Scholar 

  151. Werfel T, Aberer W, Augustin M, Biedermann T, Fölster-Holst R, Friedrichs F, Gieler U, Heratizadeh A, Kapp A, Przybilla B, Rietschel E, Schlaeger M, Schmid-Grendelmeier P, Sitters H, Staab D, Szczepanski R, Vieluf D, Voigtmann I, Worm M (2008) Leitlinien: Neurodermitis. AWMW online

  152. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J and Kapp A (2006). Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, doseresponse study. Allergy 61: 202–205

    Article  CAS  PubMed  Google Scholar 

  153. Wilson DR, Lima MT and Durham SR (2005). Sublingual immunotherapy for allergic rhinitis: systematic review and meta analysis. Allergy 60: 4–12

    Article  CAS  PubMed  Google Scholar 

  154. Zielen S, Metz D, Sommer E and Scherf H-P (2007). Kurzzeit-Immuntherapie mit Allergoiden und dem Adjuvans Monophosphoryl-Lipid-A. Allergologie 30: 1–8

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Univ. Klinik für Kinder und Jugendheilkunde Abt. für Pädiatrische Pulmologie, Allergologie und Endokrinologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Vienna, Austria

    Zsolt Szépfalusi, Saskia Gruber, Eiwegger Thomas & Eleonora Dehlink

Authors
  1. Zsolt Szépfalusi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saskia Gruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eiwegger Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zsolt Szépfalusi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szépfalusi, Z., Gruber, S., Thomas, E. et al. Allergen-spezifische Immuntherapie bei Kindern und Jugendlichen. Paediatr. Paedolog. Austria 45, 10–21 (2010). https://doi.org/10.1007/s00608-010-0254-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00608-010-0254-6

Search

Navigation